Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

wbldb

Yasuda, Hisataka¹; Shima, Nobuyuki¹; Akagawa, Nobuaki N.¹; Yamaguchi, Kyoji¹; Kinosaki, Masahiko¹; Mochizuki, Shin-Ichi¹; Omoyasu, Akihiro T¹; Yano, Kazuki¹; Goto, Masaaki¹; Murakami, Akihiko¹; Tsuda, Eisuke¹; Morinaga, Tomonori¹; Igashio, Kanji H.¹; Udagawa, Nobuyuki²; Tkahashi, Naoyuki²; Suda, Tatsuo²

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

Proc Natl Acad Sci USA. March 31, 1998;95(7):3597-3602

©1998 The National Academy of Sciences

Affiliations

¹Research Institute of Life Science, Snow Brand Milk Products Co., Ltd., 519 Ishibashi-machi, Shimotsuga-gun, Tochigi 329-0512, Japan

²Department of Biochemistry, School of Dentistry, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan
Abstract

Osteoclasts, the multinucleated cells that resorb bone, develop from hematopoietic cells of monocyte/macrophage lineage. Osteoclast-like cells (OCLs) are formed by coculturing spleen cells with osteoblasts or bone marrow stromal cells in the presence of bone-resorbing factors. The cell-to-cell interaction between osteoblasts/stromal cells and osteoclast progenitors is essential for OCL formation. Recently, we purified and molecularly cloned osteoclastogenesis-inhibitory factor (OCIF), which was identical to osteoprotegerin (OPG). OPG/OCIF is a secreted member of the tumor necrosis factor receptor family and inhibits osteoclastogenesis by interrupting the cell-to-cell interaction. Here we report the expression cloning of a ligand for OPG/OCIF from a complementary DNA library of mouse stromal cells. The protein was found to be a member of the membrane-associated tumor necrosis factor ligand family and induced OCL formation from osteoclast progenitors. A genetically engineered soluble form containing the extracellular domain of the protein induced OCL formation from spleen cells in the absence of osteoblasts/stromal cells. OPG/OCIF abolished the OCL formation induced by the protein. Expression of its gene in osteoblasts/stromal cells was up-regulated by bone-resorbing factors. We conclude that the membrane-bound protein is osteoclast differentiation factor (ODF), a long-sought ligand mediating an essential signal to osteoclast progenitors for their differentiation into osteoclasts. ODF was found to be identical to TRANCE/RANKL, which enhances T-cell growth and dendritic-cell function. ODF seems to be an important regulator in not only osteoclastogenesis but also immune system.
Links

DOI: 10.1073/pnas.95.7.3597

PubMed: 9520411

WoS: 000072848500051
History

Received: 1997-12-15

Cited Works (1)

Year	Entry
1990	Udagawa N, Takahashi N, Akatsu T, Tanaka H, Sasaki T, Nishihara T, Koga T, Martin TJ, Suda T. Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc Natl Acad Sci USA. September 1, 1990;87(18):7260-7264.

Cited By (46)

Year	Entry
2006	Robling AG, Castillo AB, Turner CH. Biomechanical and molecular regulation of bone remodeling. Annu Rev Biomed Eng. 2006;8:455-498.
2011	Feng X, McDonald JM. Disorders of bone remodeling. Annu Rev Pathol. 2011;6:121-145.
2005	Keller H, Kneissel M. SOST is a target gene for PTH in bone. Bone. August 2005;37(2):148-158.
2008	You L, Temiyasathit S, Lee P, Kim CH, Tummala P, Yao W, Kingery W, Malone AM, Kwon RY, Jacobs CR. Osteocytes as mechanosensors in the inhibition of bone resorption due to mechanical loading. Bone. January 2008;42(1):172-179.
2020	Sugisaki R, Miyamoto Y, Yoshimura K, Sasa K, Kaneko K, Tanaka M, Itose M, Inoue S, Baba K, Shirota T, Chikazu D, Kamijo R. Possible involvement of elastase in enhanced osteoclast differentiation by neutrophils through degradation of osteoprotegerin. Bone. March 2020;132:115216.
2021	Siddiqui JA, Le Henaff C, Johnson J, He Z, Rifkin DB, Partridge NC. Osteoblastic monocyte chemoattractant protein-1 (MCP-1) mediation of parathyroid hormone's anabolic actions in bone implicates TGF-β signaling. Bone. February 2021;143:115762.
2021	Wang JS, Yoon S-H, Wein MN. Role of histone deacetylases in bone development and skeletal disorders. Bone. February 2021;143:115606.
2020	Xin Y, Liu Y, Liu D, Li J, Zhang C, Wang Y, Zheng S. New function of RUNX2 in regulating osteoclast differentiation via the AKT/NFATc1/CTSK axis. Calcif Tiss Int. May 2020;106(5):553-566.
2021	Carrillo-López N, Martínez-Arias L, Fernández-Villabrille S, Ruiz-Torres MP, Dusso A, Cannata-Andía JB, Naves-Díaz M, Panizo S; European Renal Osteodystrophy (EUROD) Workgroup. Role of the RANK/RANKL/OPG and Wnt/β-catenin systems in CKD bone and cardiovascular disorders. Calcif Tiss Int. April 2021;108(4):439-451.
1999	Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev. June 1999;20(3):345-357.
2000	Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. April 2000;21(2):115-137.
2020	Møller AMJ, Delaissé J-M, Olesen JB, Canto LM, Rogatto SR, Madsen JS, Søe K. Fusion potential of human osteoclasts in vitro reflects age, menopause, and in vivo bone resorption levels of their donors: a possible involvement of DC-STAMP. Int J Mol Sci. 2020;21(7):6368.
2002	Zhao S, Kato Y, Zhang Y, Harris S, Ahuja SS, Bonewald LF. MLO‐Y4 osteocyte‐like cells support osteoclast formation and activation. J Bone Miner Res. November 2002;17(11):2068-2079.
2007	Duvall CL, Taylor WR, Weiss D, Wojtowicz AM, Guldberg RE. Impaired angiogenesis, early callus formation, and late stage remodeling in fracture healing of osteopontin‐deficient mice. J Bone Miner Res. February 2007;22(2):286-297.
2020	Loftus A, Cappariello A, George C, Ucci A, Shefferd K, Green A, Paone R, Ponzetti M, Delle Monache S, Muraca M, Teti A, Rucci N. Extracellular vesicles from osteotropic breast cancer cells affect bone resident cells. J Bone Miner Res. February 2020;35(2):396-412.
2020	Qian Z, Zhang Y, Kang X, Li H, Zhang Y, Jin X, Gao X, Xu M, Ma Z, Zhao L, Zhang Z, Sun H, Wu S. Postnatal conditional deletion of Bmal1 in osteoblasts enhances trabecular bone formation via increased BMP2 signals. J Bone Miner Res. August 2020;35(8):1481-1493.
2003	Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest. April 2003;111(8):1221-1230.
2002	Nakamura H, Tsuji T, Hirata A, Yamamoto T. Localization of osteoprotegerin (OPG) on bone surfaces and cement lines in rat tibia. J Histochem Cytochem. 2002;50(7):945-953.
2002	Seeman E. Pathogenesis of bone fragility in women and men. Lancet. May 25, 2002;359(9320):1841-1850.
2011	Xiong J, Onal M, Jilka RL, Weinstein RS, Manolagas SC, O'Brien CA. Matrix-embedded cells control osteoclast formation. Nat Med. November 2011;17(10):1235-1242.
1999	Kong Y-Y, Yoshida H, Sarosi I, Tan H-L, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. January 28, 1999;397(6717):315-323.
2003	Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. May 15, 2003;423(6937):337-342.
2020	Miller PD, Pannacciulli N, Malouf-Sierra J, Singer A, Czerwiński E, Bone HG, Wang C, Huang S, Chines A, Lems W, Brown JP. Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates. Osteoporos Int. January 2020;31(1):181-191.
2021	McAlpine M. Tea Types and Their Effects on in Vitro Mineralization and in Vivo Bone Structure and Density [PhD thesis]. Brock University; 2021.
2015	Scully N. Differentiation of Osteoblasts to Osteocytes in 3D Type I Collagen Gels: A Novel Tool to Study Osteocyte Responses to Mechanical Loading [PhD thesis]. Cardiff, UK: Cardiff University; April 2015.
2007	Yuan Y. The Differential Effects of Two Critical Osteoclastogenesis Stimulating Factors on Bone Biomechanics [PhD thesis]. Clemson, SC: Clemson University; May 2007.
1998	Bateman TA. Cytokine Therapies for Short-Term Disuse Osteopenia Models in Murines [PhD thesis]. University of Colorado; 1998.
2014	Lee HG. Innate Immune-Like Function of Osteogenic Cells and Their Effects on Inflammatory Osteolysis [PhD thesis]. Columbia University; 2014.
2012	Slyfield CR Jr. The Biomechanics of Bone Turnover [PhD thesis]. Ithaca, NY: Cornell University; January 2012.
2005	Day JS. Bone Quality: The Mechanical Effects of Microarchitecture and Matrix Properties [PhD thesis]. Erasmus University Rotterdam; 2005.
2007	Duvall CL. The Role of Osteopontin in Postnatal Vascular Growth: Functional Effects in Ischemic Limb Collateral Vessel Formation and Long Bone Fracture Healing [PhD thesis]. Atlanta, GA: Georgia Institute of Technology; May 2007.
2023	Nilsson K. NOTUM and RSPO3 in Bone: WNT Signaling Modulators Regulating the Skeleton [PhD thesis]. University of Gothenburg; 2023.
2009	Miller ES. The Role of E2f4 in Cell Cycle Exit and Bone Development [PhD thesis]. Cambridge, MA: Massachusetts Institute of Technology; June 2009.
2019	Piet J. Restoring Mechano-Adaptation in Aged Murine Bone [PhD thesis]. Northeastern University; March 2019.
2005	Pitner ND. Evaluation of the Role of Low-Density Lipoprotein Receptor-Related Protein 5 (lrp5) in Regulating Bone Mass [PhD thesis]. Purdue University; December 2005.
2007	Malone AMD. Mechanotransduction Mechanisms in Bone Cells [PhD thesis]. Stanford University; August 2007.
2012	Uzer G. Role of Fluid Shear Modulation on Bone Cell Metabolism During High-Frequency Oscillatory Vibrations [PhD thesis]. Stony Brook, NY: Stony Brook University; December 2012.
2017	Morse AR. The Role of Wnt/β-Catenin Antagonists - Sclerostin and DKK1 - in Bone Homeostasis and Mechanotransduction [PhD thesis]. University of Sydney; 2017.
2012	Bhandari KH. Bone Targeting Salmon Calcitonin Analogues as Drug Delivery Systems for Bone Disease [PhD thesis]. Edmonton, AB: University of Alberta; 2012.
2004	Hoffler CE II. In Pursuit of Accurate Structural and Mechanical Osteocyte Mechanotransduction Models [PhD thesis]. University of Michigan; 2004.
2016	Vrahna C. Investigating the Effects of Downstream Parathyroid Hormone (PTH) Targets on Bone Strength and Quality [PhD thesis]. Melbourne, Australia: The University of Melbourne; December 2016.
2010	Magalhaes JKRS. The Role of Rac1 and Rac2 in Determining Bone Quality in Aged and Osteoporotic Female Mouse Models [Master's thesis]. University of Toronto; 2010.
2013	Liu CC. Effects of a New Conjugate Drug in a Rat Model of Postmenopausal Osteoporosis [Master's thesis]. University of Toronto; 2013.
2019	Ma Y-HV. Regulation of Breast Cancer Cells’ Bone-Metastatic Potential by Mechanically Stimulated Osteocytes [PhD thesis]. University of Toronto; 2019.
2019	Putnam NE. Innate Immunity and Bone Remodeling During Staphylococcus Aureus Osteomyelitis [PhD thesis]. Nashville, TN: Vanderbilt University; June 30, 2019.
2013	Ausk BJ. Identifying the Origins of Bone Loss Induced by Transient Muscle Paralysis Using Novel MicroCT Image Registration Techniques [PhD thesis]. University of Washington; 2013.